OncoMatch/Blood Cancer — Myelodysplastic (MDS)/IDH1
Blood Cancer — Myelodysplastic (MDS)IDH1 Clinical Trials
IDH1 mutations occur in approximately 5% of MDS and produce the oncometabolite 2-hydroxyglutarate, impairing normal hematopoietic differentiation. Ivosidenib (IDH1 inhibitor) demonstrated activity in relapsed/refractory IDH1-mutant MDS and is approved in IDH1-mutant AML. Trials study ivosidenib alone and in combination with azacitidine for IDH1-mutant MDS across disease-risk categories.
Top recruiting IDH1 Blood Cancer — Myelodysplastic (MDS) trials
Ranked by phase and US site count. See all 8 trials matched to your profile →
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Institut de Recherches Internationales Servier
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
M.D. Anderson Cancer Center
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
M.D. Anderson Cancer Center
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Heinrich-Heine University, Duesseldorf